What Are Triple Agonist Peptides?
Triple agonist peptides activate three hormone receptors simultaneously:
- GLP-1 (Glucagon-Like Peptide-1): Reduces appetite, slows digestion
- GIP (Glucose-Dependent Insulinotropic Polypeptide): Improves insulin response, fat metabolism
- Glucagon: Increases metabolic rate, fat burning
Current triple agonist: Retatrutide (Eli Lilly, Phase 3 trials)
Single vs Dual vs Triple Agonists
Single Agonists (Semaglutide)
- Target: GLP-1 only
- Weight loss: 10-15%
- Proven, safe, widely used
Dual Agonists (Tirzepatide, CagriSema)
- Target: GLP-1 + GIP (or GLP-1 + Amylin)
- Weight loss: 15-22.5%
- Better than single agonists
Triple Agonists (Retatrutide)
- Target: GLP-1 + GIP + Glucagon
- Weight loss: 24-28.7%
- Most effective to date
Why Triple Agonists Work Better
The glucagon addition is key:
- Boosts resting metabolic rate (burn more calories at rest)
- Enhances fat oxidation (body burns stored fat more efficiently)
- Prevents metabolic slowdown common with weight loss
- Synergistic effects with GLP-1 and GIP
Are Triple Agonists Safe?
Clinical trial data shows: Retatrutide's side effects are similar to dual agonists (tirzepatide). Adding glucagon didn't significantly worsen GI side effects.
Caveat: Triple agonists have less real-world safety data than semaglutide (5+ years) or tirzepatide (2+ years).
When Will Triple Agonists Be Available?
- Retatrutide: 2027-2028 FDA approval expected
- Other triple agonists: Various companies developing (2028-2030+)
Should You Wait for Triple Agonists?
For most people: No. Dual agonist tirzepatide (15-22.5% weight loss) is available NOW and delivers excellent results. Start losing weight today rather than waiting 1-2 years.
You can always switch: Start tirzepatide now, lose 30-50 pounds, then switch to retatrutide when it's approved if you want even better results.